Comparison of treatment outcomes of childhood hodgkin lymphoma in two US centers and a center in Recife, Brazil

Saunders C. Hsu, Monika L. Metzger, Melissa M. Hudson, Francisco Pedrosa, Mecneide Lins, Marcia Pedrosa, Cynthia Barros, Kaline Maciel, Ching Hon Pui, Raul C. Ribeiro, Scott Howard

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

Background. Pediatric Hodgkin lymphoma (HL) has a cure rate of more than 80% in high-income countries (HIC). However, more than 80% of the world's children live in low-income countries (LIC), where the cure rate is often much lower. Procedure. We compared the outcome of HL of 371 patients treated at two pediatric oncology centers in the US to that of 62 patients treated at one center in Recife, Brazil (IMIP) to determine whether the same treatment strategy should be used in both high-income and LIC. The logrank test was used to compare event-free and overall survival. Results. The percentages of patients with unfavorable disease at each center were similar (P = 0.72). Patients with favorable disease at IMIP had estimated 5-year survival rates comparable to those of the US centers (100% and 99%, respectively). Among patients with unfavorable disease, those treated at IMIP had a 5-year event-free survival (EFS) rate of 60%, compared to 78% at the US centers; (P = 0.08). The 5-year survival estimate after relapse was 25% at IMIP versus 61% at the US centers (P = 0.08). The 5-year overall survival for patients with unfavorable disease was 72% at IMIP versus 90% at the US centers (P = 0.01). Conclusions. Intensive frontline therapy should be considered for patients with unfavorable HL in LIC where the relapse rate is high and the salvage rate is low, provided that supportive care is adequate.

Original languageEnglish (US)
Pages (from-to)139-144
Number of pages6
JournalPediatric Blood and Cancer
Volume49
Issue number2
DOIs
StatePublished - Aug 2007
Externally publishedYes

Fingerprint

Hodgkin Disease
Brazil
Disease-Free Survival
Survival Rate
Pediatrics
Recurrence
Survival
Therapeutics

All Science Journal Classification (ASJC) codes

  • Cancer Research
  • Pediatrics, Perinatology, and Child Health
  • Hematology

Cite this

Comparison of treatment outcomes of childhood hodgkin lymphoma in two US centers and a center in Recife, Brazil. / Hsu, Saunders C.; Metzger, Monika L.; Hudson, Melissa M.; Pedrosa, Francisco; Lins, Mecneide; Pedrosa, Marcia; Barros, Cynthia; Maciel, Kaline; Pui, Ching Hon; Ribeiro, Raul C.; Howard, Scott.

In: Pediatric Blood and Cancer, Vol. 49, No. 2, 08.2007, p. 139-144.

Research output: Contribution to journalArticle

Hsu, SC, Metzger, ML, Hudson, MM, Pedrosa, F, Lins, M, Pedrosa, M, Barros, C, Maciel, K, Pui, CH, Ribeiro, RC & Howard, S 2007, 'Comparison of treatment outcomes of childhood hodgkin lymphoma in two US centers and a center in Recife, Brazil', Pediatric Blood and Cancer, vol. 49, no. 2, pp. 139-144. https://doi.org/10.1002/pbc.20883
Hsu, Saunders C. ; Metzger, Monika L. ; Hudson, Melissa M. ; Pedrosa, Francisco ; Lins, Mecneide ; Pedrosa, Marcia ; Barros, Cynthia ; Maciel, Kaline ; Pui, Ching Hon ; Ribeiro, Raul C. ; Howard, Scott. / Comparison of treatment outcomes of childhood hodgkin lymphoma in two US centers and a center in Recife, Brazil. In: Pediatric Blood and Cancer. 2007 ; Vol. 49, No. 2. pp. 139-144.
@article{0280857cbb05476480f38cc4b3e82dd9,
title = "Comparison of treatment outcomes of childhood hodgkin lymphoma in two US centers and a center in Recife, Brazil",
abstract = "Background. Pediatric Hodgkin lymphoma (HL) has a cure rate of more than 80{\%} in high-income countries (HIC). However, more than 80{\%} of the world's children live in low-income countries (LIC), where the cure rate is often much lower. Procedure. We compared the outcome of HL of 371 patients treated at two pediatric oncology centers in the US to that of 62 patients treated at one center in Recife, Brazil (IMIP) to determine whether the same treatment strategy should be used in both high-income and LIC. The logrank test was used to compare event-free and overall survival. Results. The percentages of patients with unfavorable disease at each center were similar (P = 0.72). Patients with favorable disease at IMIP had estimated 5-year survival rates comparable to those of the US centers (100{\%} and 99{\%}, respectively). Among patients with unfavorable disease, those treated at IMIP had a 5-year event-free survival (EFS) rate of 60{\%}, compared to 78{\%} at the US centers; (P = 0.08). The 5-year survival estimate after relapse was 25{\%} at IMIP versus 61{\%} at the US centers (P = 0.08). The 5-year overall survival for patients with unfavorable disease was 72{\%} at IMIP versus 90{\%} at the US centers (P = 0.01). Conclusions. Intensive frontline therapy should be considered for patients with unfavorable HL in LIC where the relapse rate is high and the salvage rate is low, provided that supportive care is adequate.",
author = "Hsu, {Saunders C.} and Metzger, {Monika L.} and Hudson, {Melissa M.} and Francisco Pedrosa and Mecneide Lins and Marcia Pedrosa and Cynthia Barros and Kaline Maciel and Pui, {Ching Hon} and Ribeiro, {Raul C.} and Scott Howard",
year = "2007",
month = "8",
doi = "10.1002/pbc.20883",
language = "English (US)",
volume = "49",
pages = "139--144",
journal = "Pediatric Blood and Cancer",
issn = "1545-5009",
publisher = "Wiley-Liss Inc.",
number = "2",

}

TY - JOUR

T1 - Comparison of treatment outcomes of childhood hodgkin lymphoma in two US centers and a center in Recife, Brazil

AU - Hsu, Saunders C.

AU - Metzger, Monika L.

AU - Hudson, Melissa M.

AU - Pedrosa, Francisco

AU - Lins, Mecneide

AU - Pedrosa, Marcia

AU - Barros, Cynthia

AU - Maciel, Kaline

AU - Pui, Ching Hon

AU - Ribeiro, Raul C.

AU - Howard, Scott

PY - 2007/8

Y1 - 2007/8

N2 - Background. Pediatric Hodgkin lymphoma (HL) has a cure rate of more than 80% in high-income countries (HIC). However, more than 80% of the world's children live in low-income countries (LIC), where the cure rate is often much lower. Procedure. We compared the outcome of HL of 371 patients treated at two pediatric oncology centers in the US to that of 62 patients treated at one center in Recife, Brazil (IMIP) to determine whether the same treatment strategy should be used in both high-income and LIC. The logrank test was used to compare event-free and overall survival. Results. The percentages of patients with unfavorable disease at each center were similar (P = 0.72). Patients with favorable disease at IMIP had estimated 5-year survival rates comparable to those of the US centers (100% and 99%, respectively). Among patients with unfavorable disease, those treated at IMIP had a 5-year event-free survival (EFS) rate of 60%, compared to 78% at the US centers; (P = 0.08). The 5-year survival estimate after relapse was 25% at IMIP versus 61% at the US centers (P = 0.08). The 5-year overall survival for patients with unfavorable disease was 72% at IMIP versus 90% at the US centers (P = 0.01). Conclusions. Intensive frontline therapy should be considered for patients with unfavorable HL in LIC where the relapse rate is high and the salvage rate is low, provided that supportive care is adequate.

AB - Background. Pediatric Hodgkin lymphoma (HL) has a cure rate of more than 80% in high-income countries (HIC). However, more than 80% of the world's children live in low-income countries (LIC), where the cure rate is often much lower. Procedure. We compared the outcome of HL of 371 patients treated at two pediatric oncology centers in the US to that of 62 patients treated at one center in Recife, Brazil (IMIP) to determine whether the same treatment strategy should be used in both high-income and LIC. The logrank test was used to compare event-free and overall survival. Results. The percentages of patients with unfavorable disease at each center were similar (P = 0.72). Patients with favorable disease at IMIP had estimated 5-year survival rates comparable to those of the US centers (100% and 99%, respectively). Among patients with unfavorable disease, those treated at IMIP had a 5-year event-free survival (EFS) rate of 60%, compared to 78% at the US centers; (P = 0.08). The 5-year survival estimate after relapse was 25% at IMIP versus 61% at the US centers (P = 0.08). The 5-year overall survival for patients with unfavorable disease was 72% at IMIP versus 90% at the US centers (P = 0.01). Conclusions. Intensive frontline therapy should be considered for patients with unfavorable HL in LIC where the relapse rate is high and the salvage rate is low, provided that supportive care is adequate.

UR - http://www.scopus.com/inward/record.url?scp=34447286917&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34447286917&partnerID=8YFLogxK

U2 - 10.1002/pbc.20883

DO - 10.1002/pbc.20883

M3 - Article

VL - 49

SP - 139

EP - 144

JO - Pediatric Blood and Cancer

JF - Pediatric Blood and Cancer

SN - 1545-5009

IS - 2

ER -